ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. announced it will report its financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026. The clinical-stage biotechnology company will host an investor conference call and webcast on the same day at 4:30 p.m. ET to discuss the results and updates. Dial-in and webcast details were provided for interested participants.

ProMIS Neurosciences announced positive blinded six-month interim safety and biomarker data for its lead drug candidate, PMN310, in the PRECISE-AD Phase 1b Alzheimer’s Disease trial. The data showed a favorable safety profile with no cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all genotypes, including high-risk APOE4 carriers. Early, directionally consistent movement in disease-relevant biomarkers, including reductions in plasma pTau217 and CSF MTBR-tau243, was also observed. The company expects topline 12-month results in the first quarter of 2027.

ProMIS Neurosciences announced positive blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial for PMN310 in Alzheimer's disease patients. The drug candidate demonstrated a favorable safety profile with no cases of amyloid-related imaging abnormalities-edema (ARIA-E) and early, directionally consistent movement in disease-relevant biomarkers. These results support PMN310's differentiated mechanism targeting toxic amyloid-beta oligomers, aiming to reduce ARIA risk. The company expects to release unblinded 12-month topline data, including efficacy, in the first quarter of 2027.

ProMIS Neurosciences Inc. announced it will host a webinar on July 28, 2026, to discuss six-month blinded interim data from its PRECISE-AD Phase 1b trial for PMN310 in early Alzheimer's disease. The discussion will feature Key Opinion Leaders Dr. Will Mantyh and Dr. Michael Weiner, alongside company leadership, focusing on aggregate safety data and biomarker trends. PMN310, a lead product candidate, is designed to selectively target toxic amyloid-beta oligomers and received FDA Fast Track Designation in July 2025.

ProMIS Neurosciences announced the first human evidence of dose-dependent amyloid-beta oligomer (AβO) reduction by its lead Alzheimer’s drug candidate, PMN310. Findings from a Phase 1a trial in healthy volunteers showed a clear reduction in AβO in cerebrospinal fluid at 3 and 29 days post-dosing, representing a significant milestone in Alzheimer's treatment. The company also confirmed it is on track to present six-month blinded interim data from its ongoing Phase 1b trial in the coming weeks, with topline unblinded results anticipated in early Q1 2027.

ProMIS Neurosciences Inc. announced its participation in five healthcare conferences in June 2026, including the Jefferies Global Healthcare Conference and BIO International Convention. CEO Neil Warma will present on the company's EpiSelect™ platform and its lead Alzheimer's disease candidate, PMN310. The company also reiterated its expectation to report blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in early Q3 2026, with 12-month topline data anticipated in early 2027.

ProMIS Neurosciences Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the 2025 Stock Option and Incentive Plan, increasing the number of Common Shares available for issuance by 900,000. Additionally, seven director nominees were elected, and Baker Tilly US, LLP was ratified as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

ProMIS Neurosciences reported its Q1 2026 financial results, highlighting a significant increase in its cash position due to a private placement. The company secured $70.1 million in net proceeds from a January 2026 PIPE offering, boosting cash to $63.8 million by March 31, 2026, up from $6.1 million at year-end 2025. Despite an increased net loss of $8.2 million for the quarter, the company expects its current capital to fund operations through 2027, though additional funding will be required for future clinical activities.

ProMIS Neurosciences announced its Q1 2026 financial results and provided a corporate update, highlighting the successful closure of a PIPE financing that secured up to $175 million, including potential warrant exercises. This financing is expected to fund the company through 2027, covering the completion of its ongoing PRECISE-AD Phase 1b clinical trial for Alzheimer's disease. The trial is fully enrolled, with a blinded 6-month interim analysis expected in early Q3 2026 and 12-month top-line data in early 2027. The company reported a net loss of $8.2 million for the quarter, an increase from $7.3 million in the prior year, but ended with $63.8 million in cash and cash equivalents.